With access to anonymised real-world evidence through multicentre data analysis, we provide first-class data quality and seamless integration with existing sources.

 

Our technology enables its users to structure healthcare data from various sources into the OMOP Common Data Model. This innovation allows life science partners to use 100% anonymised patient data, breaking down barriers between healthcare and life science.

Simple & Fast Data Evaluation

Our streamlined data evaluation process facilitates the rapid extraction of valuable insights from a wide range of clinical research data, including real-world healthcare data and patient reported outcome measures. Researchers can analyse actual anonymised treatment data to gain insights into trends and disease patterns. This helps them to develop optimal solutions for a wide range of conditions.

High-Quality Data

syndena meets the highest standards of clinical data quality through structured real-world evidence (RWE) and the seamless integration of various data sources. Our experts are always working to advance syndena insights, ensuring our data quality is unsurpassed. By employing rigorous plausibility checks, consistency checks and error minimisation processes, our team upholds the highest standards for reliable real-world evidence in healthcare and clinical research.

syndena collaborative use of data

Collaborative Use of Data

Our collaborative approach supports the efficient use of healthcare data to develop custom-fit solutions. We focus on achieving interoperability between existing data sources and technical systems to enable a seamless data exchange. syndena insights efficiently enables collaborative multicentre data analysis with other research centres and life science partners.

Data Protection: GDPR-Compliant

syndena complies with strict ethical guidelines and data protection standards. Our system is developed and hosted in Austria and Germany. All patient data remains within the clinical environment to comply with medical data protection regulations. Before data can be used collaboratively by other research centres or life science partners, all data is fully anonymised, ensuring it cannot be attributed to individuals.

How Does syndena insights Work?

Leveraging AI and NLP, syndena automates the structuring of clinical data by identifying key information in clinical notes uploaded by the clinical teams. The hospitals remain in full control of the patients’ data, while the dashboard supplies life science institutions and research partners with aggregated, anonymised results. The entire process is fully GDPR-compliant, ensuring the highest level of protection and confidentiality for health-related data.

Benefit from a Wide Range of Data Sets

syndena insights hosts a comprehensive repository of patient data, spanning a broad range of indications and incorporating patient reported outcome measures. Beyond mere data, it serves as the cornerstone for informed decision-making, pioneering research and establishing a data-driven healthcare ecosystem.

+ 100,000 anonymised entries of patient data

+ 15 years of follow in multiple indications

+ 6,000 ePROMS

The data from syndena insights can be used especially for the following business units in life science and pharma:

Clinical Trial Design

syndenas utilization of real-world data enhances the precision of clinical trial planning.

Synthetic Control Arm
Our dataset can be used to generate synthetic control arms, facilitating the effectiveness of new treatments.

Market Access

Our dataset facilitates the launch and development of comprehensive HEOR value dossiers for the life science and pharmaceutical industries.

Medical Affairs

Our dataset enables the extraction of profound insights into clinical outcomes and real-world evidence pertaining to products.

Medical Domains of sydnena insights.

syndena insights already provides data for a large number of therapeutic areas, and more are being added.

Hematology

Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma (FL)

Diffuse Large B-Cell Lymphoma (DLBCL)

Multiple Myeloma (MM)

AL Amyloidosis

syndena therapeutic areas cardiology

Cardiology

(h)ATTR Amyloidosis

Chronic Inflammatory Cardiomyopathy

syndena therapeutic areas gastroenterology

Gastroenterology

Crohn´s Disease (CD)

Colitis Ulcerosa (CU)

Neurology

Myasthenia Gravis

Multiple Sclerosis

Rheumatology

Rheumatoid Arthritis

„For over 10 years, syndena / OncoTyrol has been a highly trusted and recommendable partner, enabling us to deepen our understanding about which treatment trends and which patient outcomes evolved over the years in various real world settings. When you partner with them, their innovative methodologies, along with their scientific approach will lead to excellent project outcomes.“

 

Uwe Händel, BeiGene, Associate Medical Director Austria
„Syndena works professionally and always adheres to the highest quality standards in implementation. What I particularly appreciate in our collaboration is the pronounced customer orientation and the ability to implement customized projects in a timely manner.“

 

Bernd Schöpf, Gilead, Associate Director Medical Affairs
„The AIDA registry presents an incredibly valuable real-world data resource for rare diseases such as amyloidosis. The data analysis and scientific expertise of Syndena provided excellent RWE.“

 

Luis Zurkirchen, Medical Advisor, Alexion Pharma GmbH
“We are extremely pleased with our collaboration with Syndena. Their professional approach and high quality of work have impressed us and exceeded our expectations. The appreciation they have shown for our partnership has contributed to the smooth execution of our projects and the achievement of great results. We look forward to future projects with Syndena and are confident that their expertise and dedication will continue to help us reach our goals.”

 

Maik Scherholz, Senior Medical Affairs Scientist, malignant Hematology, Pfizer
“Syndena offered unique data that were not available elsewhere and helped address some of our critical research questions. We also found the research term to be incredibly flexible and collaborative.”

 

Ulrike Sager, Head Market Access Germany and Austria bei Oncopeptides AB

syndena insights is only one login away

To access the syndena insights global dashboard from the anonymized and real an account with access data.

Let's Start Unleashing the Full Power of Your Data

We’re here to help! We got your back!

syndena – for Data-Driven Treatments in the Healthcare Sector

We firmly believe that data-driven decisions based on real-world evidence drive progress in patient outcomes and scientific research. We are committed to turning this belief into reality. Explore how syndena offers more than just a solution for structuring data.

find out more

We care about your privacy

For a proper online-experience we recommend you to accept the usage of cookies. Some cookies are necessary for the functionality of this website and can therefore not be deselected. Other cookies help us to personalize the content and to analyze the usage of our website. Third-party cookies will allow advertising personalised especially for you.

For further information please see our „cookie policy“ or our „privacy policy“. You can manage your consent and settings at any time by going to „cookie preferences“ at the bottom left of this page.

Necessary cookies help make a website usable by enabling basic functions like page navigation. Necessary cookies are not saved by third party services, but only transmitted to the website operator.

Cookies for statistics help us to understand how users interact with the provided content on our website and to number out the usage of each page. The relevant information is collected and passed on anonymously to our service provider.

Such cookies are collected by service providers for advertising purposes and can be used for creating target group specific advertising.